Full Title: Quantitative AI based on evolutionary computation and information theory
combined with mathematical functions yields algorithmic RNA biomarkers from a
randomized rheumatoid arthritis clinical trial, accurately predicting individual patient
responses to anti-TNF treatment, to enable precision medicine

Short Title: Algorithmic RNA biomarkers from a clinical trial accurately predict
individual patient responses to anti-TNF treatment

Kevin Horgan[1]*, Michael F. McDermott[2], Douglas Harrington[3], Vahan Simonyan[4],
Patrick Lilley[1,5]

[1] Liquid Biosciences, 26895 Aliso Creek Road B800, Aliso Viejo, CA 92656
[2] Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds,
LS9 7TF, Leeds, UK.
[3] Montana Department of Health and Human Services, Helena, MT 59601
[4] Department of Biochemistry and Molecular Medicine, George Washington School
of Medicine and Health Sciences, Washington, D.C. 20052
[5] Ignite Biomedical, Medfield, MA 02052
16
17 *kevinh@liquidbiosciences.com

Abstract

Background: The routine derivation of novel biomarkers from therapeutic clinical trials to accurately predict individual patient's responses, would be a significant advance. We hypothesized that quantitative AI software designed to analyze complex biomedical data, based on evolutionary computation and information theory combined with a wide range of mathematical functions, could identify algorithmic biomarkers from baseline data in a clinical trial, predictive of individual responses to therapy.

Methods and Findings: A previously published randomized double-blind placebo controlled clinical trial was analyzed. Patients with active rheumatoid arthritis (RA) on a stable dose of methotrexate and naive to anti-tumor necrosis factor (TNF) biologic therapy, were randomized to receive infliximab or placebo. The primary endpoint was synovial disease activity assessed by magnetic resonance imaging. Secondary endpoints included the Disease Activity Score 28 (DAS28). Baseline peripheral blood gene expression variable data were available for 59 patients, plus the treatment variable, infliximab or placebo, yielding a total of 52,379 baseline variables. The binary dependent variable for analysis was DAS28 response, defined by a decrease in DAS28 score of 1.2, at 14 weeks. At 14 weeks, 20 of the 30 patients receiving infliximab had responded, and ten of the 29 patients receiving placebo had responded. The software derived a discovery algorithm, with 4 gene expression variables plus treatment assignment and 12 mathematical operations, that correctly predicted responders versus non-responders for all 59 patients with available gene expression data, giving 100% accuracy, 100% sensitivity and 100% specificity. We present the discovery algorithm to provide transparency and to enable verification. Excluding the 4 gene expression variables, we then derived similarly accurate predictive algorithms with 4 other gene expression variables. We then tested the hypothesis that the software could derive algorithms as predictors of treatment response to anti-TNF biologic therapy using just these 8 discovery gene expression variables using previously published independent datasets from 6 RA studies. In each validation analysis, the accuracy of the algorithmic

predictors we derived surpassed those benchmarks previously reported by the original study

authors using a variety of approaches, including machine learning.

Conclusions and Relevance: Software based on evolutionary computation and information

theory combined with mathematical functions, summarized the outcome of a clinical trial,

with transparent biomarker algorithms derived from baseline data, correctly predicting the

clinical outcome for all 59 RA patients. The biomarker variables were validated in 6

independent RA cohorts and are now in development as a clinical test. This approach may

simplify and expedite the discovery and development of companion diagnostic algorithmic

biomarkers accurately predicting individual treatment response, - potentially accelerating the

deployment of precision medicine. Original Trial Registration used for

analysis: ClinicalTrials.gov registration: NCT01313520

81
82

Introduction

The completion of the Human Genome Project in 2003 was accompanied by optimism that a profusion of novel diagnostics and therapeutics would rapidly ensue. Technical innovations and digitization have since produced vast amounts of data without clearly impacting the trajectory of clinical advances [1]. The lack of predictive biomarkers with sufficient accuracy to inform therapeutic decisions for individual patients is an unresolved problem, thwarting the realization of the vision of precision medicine [2,3]. Why has the explosive growth in biomedical data not enabled greater progress, especially with respect to the discovery and development of predictive biomarkers? The typical explanation is the daunting complexity of biology.

Living organisms are complex systems, containing orders of magnitude more information than non-living entities [4]. Biological functions, including disease and drug responsiveness, result from complex networks of cellular and molecular interactions that can potentially be described mathematically, reflecting mechanisms and constraints under which biological systems operate [5-9]. These interactions are typically nonlinear and multi-dimensional which greatly complicates their analysis and definition [10-13]. This explains why single variable biomarkers are typically inadequate providers of clinically useful predictive insight [11].

Identifying causal factors from data is an inverse problem. What would an ideal analytic solution to the inverse problem as applied to biological complexity to yield actionable insight, including predictive biomarkers, look like? In a complex system, information is present in the relationships between components, as well as in the individual components themselves. An effective analytic solution would reveal the specific molecular networks that underly biological functions, diseases and therapeutic effects respectively. The analytic approach would not assess the components in isolation. Instead, it would identify the relevant components in terms of their mathematical relationships with other components to reflect

accurately their frequently non-linear nature. In essence, the solution would distil essential

information into transparent explanatory and predictive quantitative algorithms, which could

then be translated into clinical tests.

Such an analytic solution could be applied to all forms of biomedical data, including clinical

trial data. Randomized clinical trial outcomes are conventionally analyzed using a pre-

specified hypothesis and statistical tests, based on the average overall response, in order to

assess whether treatment is effective at a population level. Much information from clinical

trials is neglected with this approach, resulting in a lack of guidance for clinicians and

patients as to which individuals might benefit from the therapy. The ability to summarize

clinical trial data in terms of transparent summary, quantitative, easily validated, algorithms

predictive of individual patient outcomes would have transformative potential for informing

both clinical practice and research.

Since machine learning is not adequate, in part because of its black box solutions, and in

part because prevalent methods do not have a broad palette of mathematical functions to

characterize many interactions present in real-world systems, we developed a novel

approach [14,15]. Our approach to devising a novel analytic solution was based on an

evolutionary computation foundation fused with mathematics, the science of complex

emergent systems, information theory and its subset, algorithmic compression theory. The

software incorporated a comprehensive set of mathematical functions, to produce

transparent interpretable predictive algorithms from complex biomedical data, specifically

designed to model the nonlinear and high dimension relationships that define complex

emergent systems. The algorithms produced are verifiably accurate mathematical solutions

predicting the outcome of interest.

To test the software, we applied it to a published placebo-controlled clinical trial of infliximab

in RA, conducted by a pharmaceutical company with baseline peripheral blood

transcriptomic data [16,17]. Infliximab is a monoclonal anti-TNF alpha antibody effective in

treating a range of immune mediated disease including RA. The hypothesis was that the

software would produce transparent, interpretable, discovery algorithms predictive of

individual treatment responses that could be independently validated. We selected this trial

because it was randomized, and placebo controlled with tens of thousands of RNA data

points available for each patient to provide a rigorous test. The software produced a

discovery algorithm comprised of biomarker measurements, a clinical variable and

mathematical functions, with 100% accuracy in predicting both infliximab and placebo

treatment outcomes. The biomarkers were four RNA gene expression variables. When those

four gene expression variables in the original algorithm were excluded from subsequent

analyses, using exactly the same analytic approach, additional algorithms were derived, with

four different gene expression variables, and similar 100% predictive accuracy.

Having identified the eight discovery gene expression variables, we then hypothesized that

applying the software using only those eight variables, to previously published data from six

additional RA studies containing baseline gene expression data, would derive accurate

predictors of clinical outcomes following anti-TNF treatment. In each case, using just these

eight gene expression variables, the software provided an algorithm more predictive of

treatment response than reported in the original publications, thereby independently

validating both the gene expression variables as response predictors, and the superior

predictivity of our methodology relative to the various approaches, including different

variants of machine learning, previously reported.

Methods

Discovery Cohort

The discovery cohort was from a published, four European center, randomized,

double-blind placebo-controlled trial of infliximab, in RA patients naïve to biologic

therapy following an inadequate response to methotrexate [16,17]. Active disease

was defined as at least 6 tender and 6 swollen joints, with a rheumatoid arthritis

magnetic resonance imaging score of ≥ 1 in the radio-carpal or intercarpal joints, as

objective confirmation of disease activity. The patients were ~~all~~ on stable doses of

methotrexate, steroids, and/or non-steroidal anti-inflammatory drugs. At weeks 0, 2,

6, and 14, the participants received either infliximab 3 mg/kg or placebo. The

patients were of mean age of 50 years~~,~~ predominantly female (92%), and

rheumatoid factor positive (91.5%), with a mean baseline DAS28 score of 6.2. The

primary endpoint was a magnetic resonance imaging assessment of disease activity.

This endpoint was not used in our analysis, because the imaging data were not

available for individual patients. The trial used the European League against

Rheumatism (EULAR) DAS28 score to evaluate response, defined as a decrease of

≥ 1.2, as a binary dependent variable for the analysis at 14 weeks, yes or no.

Baseline peripheral blood gene expression data for 59 patients were available plus

an additional variable reflecting treatment, either infliximab or placebo, resulting in a

total of 52,379 potentially independent variables.

Validation Cohorts

To independently validate the gene expression variables in the discovery algorithms,

we applied these variables to 6 previously published studies with available baseline

gene expression data from patients with active RA, treated with anti-TNF therapies

[18-23]. These studies were done in different geographies, used different

methodologies to process the samples and gene expression data, had different

endpoints, and in some cases, used different anti-TNF therapies [18-23]. Summary

details on the discovery and validation studies are provided in Table 1, with details

available in the original publications [18-23].

Microarray data

The gene expression profiles analyzed were downloaded from the GEO database.
Because all the data used were de-identified and publicly available, neither ethics
committee approval nor informed consent were required. Datasets were downloaded
and transposed so that gene expression values and clinical variables were changed
from rows to columns, and subject records were changed from columns to rows.
Data files were saved in CSV format and imported into the software for analysis,
without any pre-processing of the biomarker measures.

Analysis

The software is a quantitative analytic platform based on evolutionary computation,
designed as a scalable, unbiased methodology to produce transparent algorithms
based on mathematical relationships from complex data, without any prior
assumptions other than the patient selection criteria and study design used in the
studies yielding data for analysis. The software fuses evolutionary principles, signal
processing mathematical functions with information theory, and requires no domain
expertise or prior knowledge of the nature of a problem in terms of explanatory
variables, dimensionality or underlying mathematical relationships. A distinctive
feature is that the software uses all available data to derive the algorithms, without
any filtering process to exclude variables based on commonly used thresholds or
feature selection methods. This enables the identification of variables typically
discarded by feature selection methods used in biomarker discovery. This includes
such methods' tendency to discard potential explanatory variables, with relatively low
expression or non-linear relationships to the outcome, but which may be functionally
important because of the non-linear and binary threshold interactions pervasive in

complex biologic systems. The software identifies key variables in the context of

their mathematical relationships with each other and associated with outcomes of

interest. The software automatically excludes overfitted algorithms. The software

automatically divides the data into three distinct, random subsets that are

sequentially processed: a training set, a selection set, and a test set. Analysis of the

training subset provides an ensemble of candidate algorithms, which are then

evaluated on the selection subset, to select a final algorithm, which is then validated

on the test set. An overfitted algorithm would not be validated on the test set,

ensuring that overfitted algorithms are not selected. The training, selection, and test

data subsets are scrupulously segregated, to avoid any information leakage between

the discrete components of the process. In the discovery analysis of the MacIsaac et

al. data, there were 18 patients in the training set, 21 in the selection set and 20 in

the test set (Table 2).

The 8 variables in the discovery algorithms were then applied to the analyses of six

additional published data sets in patients with RA, using both baseline gene

expression data and response outcomes to anti-TNF therapy, for independent

validation. The intent was to prospectively validate the 8 variables and also to

benchmark the predictivity of the algorithmic biomarkers that incorporated them,

relative to prior predictors using traditional analytic approaches, such as the different

types of machine learning.

Findings

Discovery Analysis: Derivation of MacIsaac et al Algorithm

The software initially yielded an algorithmic biomarker set with five variables and

twelve sequential mathematical instructions as shown in Table 3. The Gene

expression variables expressed quantitatively: *SPTY2D1*, *Clorf105*, *KCTD4* and

UL84 and treatment assignment: infliximab or placebo.

The algorithm is presented in the form of an equation:

$$\left\{ \frac{C1orf105}{\left[\frac{7}{treatment+2}+KCTD4-7+SPTY2D1,\frac{\sin(UL84)}{UL84}\right]^{\left[\frac{\sin(UL84)}{UL84}<\frac{\sin(19)}{19}\right] AND \left[C1orf105<\frac{7}{treatment+2}\right]}_{\left[\frac{\sin(UL84)}{UL84}\geq\frac{\sin(19)}{19}\right] OR \left[C1orf105\geq\frac{7}{treatment+2}\right]}} + \frac{7}{5} \right\} < 0$$

To facilitate validation the algorithm is also shown as a schematic in Fig 1.

A calculation for an individual patient, with a resulting value of less than zero

indicated treatment non-response, and a value of zero or more indicated treatment

response. The baseline values for the four gene expression markers, for each of the

59 patients, are present in supplementary data to enable verification of the algorithm.

These variables were not those with the highest levels of expression. Agnostic

evolutionary selection of treatment as a variable, either infliximab or placebo, into the

predictive algorithm is evidence that the treatment has a mathematically significant

impact on the response outcome for some patients. Although expected a priori, the

treatment assignment variable was selected agnostically by the evolutionary

process, and not pre-specified. Users of the software cannot influence or require any

variable to be incorporated into an algorithm.

The performance metrics for the components of the discovery analyses are shown in

Table 2, with 18 patients in the training set, 21 in the selection set and 20 in the test

set. The overall accuracy was 100% with 100% sensitivity and specificity. Repeat

analyses consistently yielded exactly the same variables, and the mathematical

instructions encoded in all algorithms were, without exception, mathematically

equivalent in terms of binary outcome: response or non-response. Omission of any

of the mathematical instructions from the algorithm degraded predictivity. Therefore,

the algorithm was optimized and devoid of superfluous calculations. Accuracy and

reliability were consistent across training, validation and test sets analysed. When

the initial four gene expression variables were excluded from subsequent analyses,

four additional gene expression variables were identified as components of

algorithms also with 100% accuracy: PTPRC, TPM3, ARHGDIB and SIAH1 (Table

4). The software selects the minimum number of variables for maximum accuracy.

The fact that a second group of four variables provided algorithms with 100%

accuracy implies that these variables are highly correlated with the original four,

containing almost as much information. The x-y plots of the 8 individual markers

versus DAS28 change are shown in supplementary data.

Validation of gene expression variables by analysis of six independent

datasets

We then tested the hypothesis that the eight variables from the discovery algorithms

could be used to derive algorithms predicting individual treatment response

outcomes from six additional published data sets, providing independent validation

of the variables [18-23]. While the eight variables used were the same for all six

dataset analyses, distinct algorithmic operations were necessary for each validation

because of variation in quantitation instruments, measurement scale, data

preparation and normalization methods used by the original researchers across the

individual datasets. Demographic details are shown in Table 1. In each case, the

algorithms we produced had superior performance to the analyses presented in the

original publications as shown in Table 5, even though only a subset of the eight

discovery variables were available in some datasets. The original analyses used a

wide range of analytic methods including the most common ML approaches: neural

networks, support vector machines and random forests. Table 5 shows the metrics

for predictors presented in the original publications for each study as benchmarks,

compared to the metrics for the consistently superior algorithmic predictors we

derived using the data from each study.

The weighted-average sensitivity and specificity of the individual models from the

analyses we conducted across all 7 datasets, with a total of 400 subjects treated

with anti-TNF therapy, were 98.5% and 90.9%, respectively surpassing the accuracy

of all the prior published individual analyses, as shown in Fig 2. Accuracy for the

marketed TNF response predictor from two reports, Mellors et al and Jones et al, is

also presented for comparison [39,40]. This predictor consists of 23 variables and

was derived using machine learning: a combination of neural networks and random

forests. The actual model has not been published. The biomarker variables held up

across 7 patient datasets, 3 different TNF inhibitor drugs, 3 continents, multiple

ethnicities, despite differences in response criteria, RNA expression and processing

platforms and measurement scale differences.

Discussion

To address the stagnation in biomarker discovery and development we applied a novel

analytic approach, based on evolutionary computation and information theory incorporating

mathematical functions, to a placebo controlled randomized clinical trial with 52,379 baseline

gene expression variables for each of 59 patients. This provided discovery biomarker

algorithms perfectly predictive of individual responses to both active therapy and placebo.

The algorithms contained subsets of 4 variables from a total of 8 variables. The eight

discovery variables were then validated, using the same analytic approach, as components

of algorithmic predictors when applied to data from six independent clinical trials with

different TNF inhibitors, on 3 continents, in multiple ethnicities, despite differences in

response criteria, gene expression processing platforms and measurement scale

differences, thereby providing extremely high confidence as to their validity.

The MacIsaacs et al clinical trial study that provided the discovery data, was conducted by a

major pharmaceutical company but did not provide a predictor of therapeutic response, nor

did it identify any of the 8 variables we discovered as predictive [16]. In each of the six

validation analyses, our derived algorithms all containing 4 or fewer variables, had sensitivity

and specificity superior to benchmarks in the original publications, which used a variety of

mainstream analytic approaches including several machine learning approaches. None of

the publications for the six validation datasets identified the eight predictive algorithmic

biomarkers we discovered or [18-23] reported an algorithm that might be the basis for a

predictive test. To enable conclusive independent confirmation of our novel approach, we

show an example of a perfectly predictive discovery algorithm, depicted three different ways:

as a series of computer instructions, as an algebraic equation and lastly in schematic form.

The performance metrics for the algorithms we report surpass those of the marketed

predictor of anti-TNF response derived using machine learning, consisting of 23 variables,

which only identifies non-responders with a specificity of 77.3-86.8% and sensitivity of 50.0-

60.2% [39,40]. The accuracy we report defines three distinct patient subsets: the first are

anti-TNF responders, the second are placebo responders and the third are non-responders

to either anti-TNF therapy or to placebo. The potential to predict patients in these three

categories will be a focus of future studies to inform the most appropriate individualized

therapeutic interventions. The relatively simple, objective, transparent, algorithms we report,

the ease of their independent validation, and their superior performance are notable.

Precision medicine requires highly predictive biomarkers to inform treatment decisions for

individuals. With the availability of more therapeutic options, selecting the most appropriate

for an individual patient is an increasingly difficult challenge. Clinicians currently rely on trial

and error approaches. The required biomarkers to align patients with the optimal therapy,

have not been forthcoming despite huge increases in the production of biomedical data. The

asymmetry between the tens of thousands of publications describing novel biomarkers, and

the tiny fraction of these that ultimately become clinical diagnostic tests, as noted in 2014,

has persisted, representing a profound failure of biomarker discovery [2,3]. Why?

The torrent of data enabled by technical advances and digitization led to a 2008 conclusion

that the traditional scientific method needed to be refined, as standard hypothesis testing

was not compatible with the availability of "big data" [41]. Computers analyzing large

datasets can yield important previously undetectable correlations as seen in astronomy,

cosmology and meteorology [42,43]. However, in biomedical research, this approach has

yielded an underwhelming dividend as illustrated by the poverty of useful biomarkers.

We hypothesized that prior analytic approaches have not been able to reveal useful

biomarkers, because of their lack of suitability for analyzing complex biomedical data,

neglecting biology and disease as complex systems [3]. Our novel software solution differs

from the various types of machine learning, by fusing evolutionary computation with

algorithmic information theory, incorporating a wide range of mathematical functions to

directly address the non-linearity and high dimensionality of complex biomedical data

yielding transparent quantitative predictive algorithms. Transparency is necessary for both

informing medical decisions and providing scientific insight [14,15, 44], for patients,

physicians and regulators. The software automatically eliminates overfitted algorithms from

consideration. Confirmation that the selected algorithm is not overfitted is done in the third

stage of the automated process.

The application of concepts from evolutionary biology - inheritance, random variation, and

natural selection - explains why evolutionary computation can handle large high dimensional

data so efficiently [45]. Information theory is a mathematical framework for understanding

information at a fundamental level, which includes the concepts of randomness and

algorithmic compression [46, 47]. The concepts that nature, in all its manifestations, is

algorithmic, and that scientific comprehension is a process of finding predictive algorithms

that compress information into its essence, provide context for our approach [47-50]. Our

algorithmic focus is complemented by the emerging understanding that biology reflects

molecular networks that are algorithmic [51]. Biological functions, including therapeutic

response and disease are recognized to be mediated by molecular networks, variously

defined as modules, motifs or cores [5, 52-54]. It has been proposed that understanding of

molecular networks will be necessary for understanding biological information flow and that

this will require an algorithmic framework [5,51]. The incorporation of many mathematical

functions into the software allows the underlying molecular interactions, which are frequently

non-linear, to be modelled in the selected algorithms, maximizing their predictivity, without

any a priori assumptions as to their nature. The incorporation of mathematical functions into

the algorithms aligns with emerging perspectives around the need to incorporate

mathematics into biology [55]. We posit that our approach is effective with modest sample

sizes because of its focus on defining the most salient signals, represented by the

mathematical relationships between variables, which is where the information resides in

complex systems. The evolutionary foundation of our approach allows large numbers of

variables to be analyzed without the need to use arbitrary thresholds and feature selection to

eliminate variables from consideration. The number of potential permutations of algorithmic

memory registers containing only the final eight variables, combined with available

mathematical functions in the analysis we report is in excess of 10^{61}. When considering all

possible 52,379 biomarkers in the discovery dataset for each patient, the treatment arm

variable, the software's complete palette of available mathematical functions, and a limit of

only 16 instructions per algorithm, the total number of potential discovery algorithms is 4.749

times 10^{1253}. The discovery algorithm that we present, incorporates the sine function,

showing that molecular interactions underlying the response to therapy in RA can be

represented using mathematical functions that also depict relationships in other biological

contexts. This implies that the algorithm depicts a fundamental phenomenon.

We identify lower expression variables that likely have disproportionate biological effects

because of non-linear interactions that other analytic approaches cannot readily detect and

have frequently excluded from consideration. These variables, which are not well studied,

are likely to provide insights into the molecular mechanisms underlying responsiveness to

anti-TNF therapy in RA. Individually, the eight variables were not highly correlated with

response, and would not be useful response predictors either individually, or collectively in

the absence of the mathematical components of the algorithm. As well as revealing

predictive algorithmic biomarkers, our approach may also enable the identification and

understanding of the molecular networks mediating disease and therapeutic effects. These

algorithms may help with the identification and prioritization of novel therapeutic targets,

particularly those that might be amenable to emerging approaches that modulate specific

RNA transcripts.

There are no prior reports directly linking SPTY2D1, KCTD4, and c1orf105 to either RA,

immune-mediated diseases or to responses to therapy [24-28]. TPM3 has been reported as

an autoantigen in RA, and to be associated with both myopathy and renal cancer [33-35].

ARHGDIB expression is upregulated in RA, whereas SIAH1 is downregulated [36-38].

TPM3, ARHGDIB and SIAH1 have not been associated with therapeutic outcomes. Prior

cytomegalovirus exposure has been associated with poor responses to therapy in early RA

[29,30] which may explain the UL84 gene variable as it encodes for a cytomegalovirus

protein. Mutations in PTPRC, also known as CD45, have been associated with RA patient

response to anti-TNF therapy [31,32]. The variables we report are in development as

components of a clinical PCR test using clinical grade instruments and protocols. PCR tests

are versatile and reliable for deployment in clinical laboratories. The discovery algorithm,

derived on research instruments such as we have presented is not appropriate for clinical

use, as its primary purpose is to identify the most informative variables. Research-stage

instruments have different quantitation levels, dynamic range and reliability than clinical-

grade assay processes and technology. So the clinical test will require derivation of novel

algorithms, which will then need to be prospectively validated for clinical use. We envision

that the clinical test will provide the basis for an ensemble of algorithms, each predictive of

different specific clinical endpoints, in addition to DAS28, at different time points providing a

comprehensive efficacy profile for individual patients, most informative to clinicians,

maximizing clinical relevance. We are applying the same gene expression variables to other

diseases responsive to anti-TNF therapy. Our hypothesis is that the same variables will be

the basis of algorithms predictive of individual treatment response to anti-TNF therapies in

other diseases where anti-TNF therapy is of proven efficacy, implying that the variables we

have identified are of fundamental importance in mediating the efficacy of anti-TNF therapy

in general.

Our analytic approach may provide a novel and actionable framework for the future

synchronous development of novel therapies and companion diagnostics. Proof of concept

clinical studies could routinely incorporate baseline biomarker profiling to yield transparent

algorithms predictive of both efficacy and safety signals. The predictive algorithmic

biomarkers, could then expeditiously be incorporated into, and validated in subsequent

registration studies, potentially yielding highly predictive companion diagnostics to inform

both regulatory approval and reimbursement decisions. Such algorithmic biomarkers could

also be incorporated into the product label to inform prescribing decisions for individual

patients. In the future, we envision all therapies could be accompanied by algorithmic

biomarkers, predictive of efficacy and safety endpoints of interest, to objectively and

quantitatively inform administration decisions for individual patients. The algorithmic

biomarkers could be promptly updated as new data emerges to optimize clinical utility. In

addition, clinical trial outcomes could be routinely summarized in terms of the algorithms.

We contend that translating biomedical data into actionable information requires analytic

methodology designed to yield mathematically informed algorithmic insight from complex

high dimensional non-linear data. The novel analytic approach that we present addresses

that challenge. This is the only reported method that provides transparent, simple algorithmic

biomarkers that accurately reflect biology as a complex system and quantitatively predicts

individual therapeutic responses, that can readily be translated into clinical tests. This may

have significant implications for the discovery and development of companion diagnostics

and the analysis of clinical trials.

Currently, the gulf between actual health care and that which could be provided, has

arguably never been wider [56]. We contend that bridging that gulf will require solving the

"biomarker problem" with biomarkers that reliably identify those patients who are most likely

to benefit from a particular therapy [57]. As we have shown, this will be done by a focus on

medicine as an information science, acknowledging that "to be useful, data must be

analyzed, interpreted, and acted on. Thus, it is algorithms, not data sets, that will prove

transformative [58]."

Acknowledgements: Richard Gallagher, Mary Beth Yacyshyn, Tony Ho, David

Madigan and Poul Strange provided useful comments on early versions of the

manuscript.

Author Contributions

Conceptualization: Kevin Horgan, Michael F. McDermott, Douglas Harrington,
Vahan Simonyan, Patrick Lilley.

Data curation, project administration and software: Patrick Lilley

Methodology: Kevin Horgan, Vahan Simonyan, Patrick Lilley.

Interpretation: Kevin Horgan, Michael F. McDermott, Douglas Harrington, Vahan
Simonyan, Patrick Lilley.

Formal analysis: Patrick Lilley.

Visualization: Vahan Simonyan, Patrick Lilley.

Writing – original draft: Kevin Horgan, Michael F. McDermott, Patrick Lilley.

Writing – review and editing: Kevin Horgan, Michael F. McDermott, Douglas
Harrington, Vahan Simonyan, Patrick Lilley.

Conflict of Interest

The authors declare the following competing interests: Patrick Lilley is the Chief Executive Officer, a founder and employee of Liquid Biosciences. Patrick Lilley is also a Director of Ignite Biomedical. Kevin Horgan is an unpaid advisor to Liquid Biosciences. Vahan Simonyan is an employee and owns stock in, Embleema, Inc. Vahan Simonyan is a founder, employee and owns stock in, DNA-HIVE. Michael F. McDermott and Douglas Harrington have no competing interests.

This research was funded by both Liquid Biosciences, Inc., (liquidbiosciences.com) and Ignite Biomedical, Inc (ignitebiomedical.com).

All authors participated in conceptualization of the project, interpretation of data, writing or review of the manuscript, as well as the decision to submit the manuscript for publication.

Ignite Biomedical is developing a predictive test based on the biomarkers reported in the manuscript. US patent number 11208694 has been issued to Liquid Biosciences for the biomarkers described in this report. There are no additional declarations from the authors relevant to this research relating to employment, consultancy, products in development, patents, or revenues from marketed products to declare.

Data Availability

The authors confirm that the data underlying the findings are fully available without restriction from the Gene Expression Omnibus archive: GEO accession GSE58795, GSE5392, GSE12051, GSE15258, GSE33377, GSE78068 and GSE20690. Other relevant data are in the paper and Supporting Information files. We have also made the pivotal discovery algorithm in the manuscript available in different formats and also the provided the data for the 4 gene expression variables it contains available in the Supporting Information Files to facilitate validation.

References

1. Joyner MJ, Paneth N. (2019) Promises, promises, and precision medicine *J Clin Invest* 129(3):946-948

    https://doi.org/10.1172/JCI126119

2. Barker AD, Compton CC, Poste G. (2014) The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic *Biomark Med* 2014;8(6):873-6

    https://doi.org/10.2217/bmm.14.52

3. Barker AD, Alba MM, Mallick P, et al. (2023) An Inflection Point in Cancer Protein Biomarkers: What was and What's Next *Mol Cell Proteomics* 22(7):100569

    https://doi.org/10.1016/j.mcpro.2023.100569

4. Hopfield JJ. (1994) Physics, Computation, and Why Biology Looks so Different *J Theor Biol* 171:53-60

    https://doi.org/10.1006/jtbi.1994.1211

5. Nurse P. (2008) Life, logic and information *Nature* 454(7203):424-6

    https://doi.org/10.1038/454424a

6. Nurse, P. (2014) Complexity and Biology *Cell* 157(1)272-273

    https://doi.org/10.1016/j.cell.2014.03.013

7. Berger SI, Iyengar R. (2011) Role of systems pharmacology in understanding drug adverse events *Wiley Interdiscip Rev Syst Biol Med* 3(2):129-35

    https://doi.org/10.1002/wsbm.114

8. Savic S, Caseley EA, McDermott MF (2020) Moving towards a systems-based classification of innate immune-mediated diseases *Nat Rev Rheumatol* 4:222-237

    https://doi.org/10.1038/s41584-020-0377-5

9. Coffey DS. (1998) Self-organization, complexity and chaos: The new biology for
medicine *Nat Med* 8:882-5

https://doi.org/10.1038/nm0898-882

10. Goldberger AL. (2006) Giles f. Filley lecture. Complex systems *Proc Am Thorac*
Soc 3(6):467-71

https://doi.org/10.1513/pats.200603-028MS

11. Rea TJ, Brown CM, Sing CF. (2006) Complex adaptive system models and the
genetic analysis of plasma HDL-cholesterol concentration. *Perspect Biol Med*
49(4):490-503

https://doi.org/10.1353/pbm.2006.0063

12. Mazzocchi F. (2008) Complexity in biology. Exceeding the limits of reductionism
and determinism using complexity theory *EMBO Rep* 9(1):10-4

https://doi.org/10.1038/sj.embor.7401147

13. Herrington D, Wang Y. (2023) Clinical heterogenity in the age of big data,
advanced analytics and complexity theory *Trans Am Clin Climatol Assoc* 133:56-
68

https://pmc.ncbi.nlm.nih.gov/articles/PMC10493739/

14. Wilkinson J, Arnold KF, Murray EJ et al. (2020) Time to reality check the
promises of machine learning-powered precision medicine. *Lancet Digit Health*
12:e677-e680

https://doi.org/10.1016/S2589-7500(20)30200-4

15. Price WN. (2018) Big data and black-box medical algorithms *Sci Transl Med*
10:471

https://doi.org/10.1126/scitranslmed.aao5333

16. MacIsaac K, Baumgartner R, Kang J, et al. Pre-treatment whole blood gene
expression is associated with 14-week response assessed by dynamic contrast
enhanced magnetic resonance imaging in infliximab-treated rheumatoid
arthritis patients *PLoS ONE* 9(12):e111937

https://doi.org/10.1371/journal.pone.0113937

17. Beals C, Baumgartner R, Peterfy C et al. (2017) Magnetic resonance imaging of
the hand and wrist in a randomized, double-blind, multicenter, placebo-
controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic
contrast enhanced assessments with semi-quantitative scoring *PLoS ONE*
12(12):e0187397

https://doi.org/10.1371/journal.pone.0187397

18. Lequerre T, Gauthier-Jauneau A, Bansard C et al. (2006) Gene profiling in white
blood cells predicts infliximab responsiveness in rheumatoid arthritis *Arth Res*
Ther 8: R105

https://doi.org/10.1186/ar1990

19. Julia A, Erra A, Palacio C et al. (2009) An eight-gene blood expression profile *PloS*
ONE 2009;4:e7556

https://doi.org/10.1371/journal.pone.0007556

20. Bienkowska J, Dagin G, Batliwalla F, et al. (2009) Convergent random forest
predictor: Methodology for predicting drug response from genome-scale data
applied to anti-TNF response *Genomics* 94:423-32

https://doi.org/10.1016/j.ygeno.2009.08.008

21. Toonen EJ, Gilissen C, Franke B et al. (2012) Validation study of existing gene
expression signatures for anti-TNF treatment in patients with rheumatoid
arthritis *PLoS ONE* 7(3):e33199

https://doi.org/10.1371/journal.pone.0033199

22. Nakamura S, Suzuki K, Iijima H, et al. (2016) Identification of baseline gene
expression signatures predicting therapeutic responses to three biologic agents
in rheumatoid arthritis: a retrospective observational study *Arth Res* Ther
18:159

https://doi.org/10.1186/s13075-016-1052-8

23. Tanino M, Matoba R, Nakamura S, et al. (2009) Prediction of efficacy of anti-TNF
biologic agent, infliximab, for rheumatoid arthritis patients using a
comprehensive transcriptome analysis of white blood cells *Biochem Biophys Res*
Commun 18;387(2):261-5

https://doi.org/10.1016/j.bbrc.2009.06.149

24. Ramírez-Moya J, Wert-Lamas L, Acuña-Ruíz A, et al. (2022) Identification of an
interactome network between lncRNAs and miRNAs in thyroid cancer reveals
SPTY2D1-AS1 as a new tumor suppressor *Sci Rep* 12(1):7706
656
657   https://doi.org/10.1038/s41598-022-11725-4
658

659   25. Li K, Kong R, Ma L, et al. (2022) Identification of potential M2 macrophage-
660   associated diagnostic biomarkers in coronary artery disease *Biosci Rep*
661   42(12):BSR20221394
662
663   https://doi.org/10.1042/BSR20221394
664

665   26. Zhang J, Huang X, Wang X, et al*. (2020)* Identification of potential crucial genes
666   in atrial fibrillation: a bioinformatic analysis *BMC Med Genomics* **13**(1):104
667
668   https://doi.org/10.1186/s12920-020-00754-5
669

670   27. Kim S, Noh JH, Lee MJ et al. (2023) Effects of mitochondrial transplantation on
671   transcriptomics in a polymicrobial sepsis model *Int J Mol Sci* 24(20):15326
672
673   https://doi.org/10.3390/ijms242015326
674

675   28. Zheng C, Yu X, Xu T, et al. (2023) KCTD4 interacts with CLIC1 to disrupt calcium
676   homeostasis and promote metastasis in esophageal cancer *Acta Pharm Sin B*
677   13(10):4217-4233
678
679   https://doi.org/10.1016/j.apsb.2023.07.013
680

681   29. Colletti KS, Smallenburg KE, Xu Y, et al. (2007) Human cytomegalovirus UL84
682   interacts with an RNA stem-loop sequence found within the RNA/DNA hybrid
683   region of oriLyt *J Virol* 81:7077-85
684
685   https://doi.org/10.1128/jvi.00058-07
686

687   30. Davis JM, Knutson KL, Strausbauch MA, et al. (2013) Immune response profiling
688   in early rheumatoid arthritis: discovery of a novel interaction of treatment
689   response with viral immunity *Arthritis Res Ther* 15(6):R199
690
691   https://doi.org/10.1186/ar4389
692
693
694

695 31. Cui J, Saevarsdottir S, Thomson B, et al. (2010) Rheumatoid arthritis risk allele
696 PTPRC is also associated with response to anti-tumor necrosis factor alpha
697 therapy *Arthritis Rheum* 62(7):1849-61
698
699 https://doi.org/10.1002/art.27457
700
701 32. Plant D, Prajapati R, Hyrich KL et al. (2012)Replication of association of the
702 PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK
703 cohort *Arthritis Rheum* 64(3):665-70
704
705 https://doi.org/10.1002/art.33381
706
707 33. Poulsen TBG, Damgaard D, Jørgensen MM, et al. (2020) Identification of Novel
708 Native Autoantigens in Rheumatoid Arthritis. *Biomedicines* 8(6):141
709
710 https://doi.org/10.3390/biomedicines8060141
711
712 34. Lambert MR, Gussoni E. (2023) Tropomyosin 3 (TPM3) function in skeletal
713 muscle and in myopathy *Skelet Muscle* 13(1):18
714
715 https://doi.org/10.1186/s13395-023-00327-x
716
717 35. Galea LA, Hildebrand MS, Witkowski T, et al. (2023) ALK-rearranged renal cell
718 carcinoma with TPM3::ALK gene fusion and review of the literature Virchows
719 Arch 482(3):625-633
720
721 https://doi.org/10.1007/s00428-022-03451-z
722
723 36. Ritter SY, Subbaiah R, Bebek G, et al. (2013) Proteomic analysis of synovial fluid
724 from the osteoarthritic knee: comparison with transcriptome analyses of joint
725 tissues *Arthritis Rheum* 65(4):981-92
726
727 https://doi.org/10.1002/art.37823
728
729 37. Lequerré T, Bansard C, Vittecoq O, et al. (2009) Early and long-standing
730 rheumatoid arthritis: distinct molecular signatures identified by gene-expression
731 profiling in synovia *Arthritis Res Ther* **11**:R99
732
733 https://doi.org/10.1186/ar2744
734
735
736

737   38. Badr MT, Häcker G. (2019) Gene expression profiling meta-analysis reveals novel
738   gene signatures and pathways shared between tuberculosis and rheumatoid
739   arthritis *PLoS ONE* 14(3):e0213470
740

741   https://doi.org/10.1371/journal.pone.0213470
742

743   39. Mellors T, Withers JB, Ameli A, et al. (2020) Clinical validation of a blood-based
744   predictive test for stratification of response to tumor necrosis factor inhibitor
745   therapies in rheumatoid arthritis patients *Network and Systems Medicine*
746   3.1:91-104
747

748   https://doi.org/10.1089/nsm.2020.0007
749

750   40. Jones A, Rapisardo S, Zhang L, et al. (2021) Analytical and clinical validation of an
751   RNA sequencing-based assay for quantitative, accurate evaluation of a
752   molecular signature response classifier in rheumatoid arthritis *Expert Rev Mol*
753   *Diagn* 21(11):1235-43
754

755   https://doi.org/10.1080/14737159.2021.2000394
756

757   41. Anderson, C. (2008) The End of Theory: The Data Deluge Makes the Scientific
758   Method Obsolete *Wired* 16.07 retrieved Jan 13th 2025
759

760   https://www.wired.com/2008/06/pb-theory/
761

762   42. Pontzen A. (2023) *The Universe in a Box: Simulations and the Quest to Code the*
763 *Cosmos* Riverhead Books ISBN 9780593330487
764

765   43. Doyne Farmer J. (2024) *Making Sense of Chaos: A Better Economics for a Better*
766 *World* Yale University Press ISBN 9780300273779
767

768   44. Naughton J. 2022 Machine-learning systems are problematic. That's why tech
769 bosses call them 'AI'. *The Guardian* retrieved Jan 5th 2025 from
770

771   https://www.theguardian.com/commentisfree/2022/nov/05/machine
772 learning-systems-are-problematic-thats-why-tech-bosses-call-them-ai
773

774   45. Sipper M, Olson RS, Moore JH. (2017) Evolutionary computation: the next major
775 transition of artificial intelligence? *BioData Min* 10:26
776

777   https://doi.org/10.1186/s13040-017-0147-3
778

779   46. Gleich, J. (2011) *The Information: A History, a Theory, a Flood* Pantheon Books
780 (US) ISBN 978-0-375-423-72-7

781 47. Robertson, D.S. (2003) *Phase Change: The Computer Revolution in Science and*
782 *Mathematics* Oxford University Press ISBN 0195157486
783
784 48. Zenil H, Schmidt A and Tenner J. (2017) Causality, information and biological
785 computation: an algorithmic software approach to life, disease and the immune
786 system. Chapter in *From Matter to Life: Information and Causality* pages 244-280
787 Walker SI, Davies PCW and Ellis G (eds.) Cambridge University Press. ISBN
788 9781107150539
789
790 50. Arthur, WB. (2020) Algorithms and the Shift in Modern Science. Beijer Discussion
791 Paper Series No. 269
792
793   https://beijer.kva.se/publication/algorithms-and-the-shift-in-modern-science/
794
795 51. Lim WA, Lee CM, Tang C. (2013) Design principles of regulatory networks:
796 searching for the molecular algorithms of the cell *Mol Cell* 49(2):202-12
797
798   https://doi.org/10.1016/j.molcel.2012.12.020
799
800 52. Alon U. (2007) Network motifs: theory and experimental approaches *Nat Rev*
801 *Genet* 8(6):450-61
802
803   https://doi.org/10.1038/nrg2102
804
805 53. Gallo E, De Renzis S, Sharpe J et al. (2024) Versatile system cores as a conceptual
806 basis for generality in cell and developmental biology. *Cell Syst* 15(9):790-807
807
808   https://doi.org/10.1016/j.cels.2024.08.001
809
810 54. Hartwell LH, Hopfield JJ, Leibler S, Murray AW. (1999) From molecular to
811 modular cell biology *Nature* 402(6761 Suppl):C47-52
812
813   https://doi.org/10.1038/35011540
814
815 55. Rajapakse I. (2021) Conversation with Dr Steve Smale and Dr. Lee Hartwell
816 *Notices of the American Mathematical Society* 68:9 1578-1582
817
818   https://doi.org/10.1090/noti2356
819
820 56. Angus DC, Huang AJ, Lewis RJ et al. (2024) The Integration of Clinical Trials With
821 the Practice of Medicine: Repairing a House Divided. 332(2):153-162
822
https://doi.org/10.1001/jama.2024.4088

57. Sawyers, C. (2008) The cancer biomarker problem. *Nature* **452**, 548–552

https://doi.org/10.1038/nature06913

58. Obermeyer Z, Emanuel EJ. (2016) Predicting the Future - Big Data, Machine

Learning, and Clinical Medicine. N Engl J Med. 2016;375(13):1216

https://doi.org/10.1056/NEJMp1606181

847 **Fig 1 Discovery Algorithm in Schematic Form**

848 The variables were treatment assignment (placebo versus infliximab therapy) and

849 four gene expression variables: SPTY2D1, C1orf105, KCTD4 and UL84 (Table 4).

Fig 2 Sensitivity and Specificity of Liquid Biosciences Weighted Average
analysis relative to other cited reports [18-23,39,40]

860 **Table 1 – Discovery and validation studies of blood-based gene expression data of**
861 **anti-TNF responsiveness in RA**
862

First author	MacIsaac et al (2014)[16,17]	Lequerre et al (2005)[18]	Julia et al (2009)[19]	Bienkowska et al (2009)[20]	Toonen et al (2011)[21]	Nakamura et al (2016)[22]	Tanino et al (2010)[23]
GEO accession	GSE58795	GSE5392	GSE12051	GSE15258	GSE33377	GSE78068	GSE20690
Phase	Discovery	Validation	Validation	Validation	Validation	Validation	Validation
Location	Moldova & Romania	France	Spain	USA	Netherlands	Japan	Japan
RA classification criteria	RA ACR (1987)	RA ACR (1987)	RA ACR (1987)	RA (1987)	RA ACR (1987)	RA ACR (1987) or EULAR/ACR (2010)	Not reported
Treatment	infliximab or placebo	infliximab	infliximab	infliximab adalimumab, etanercept	infliximab and adalimumab	infliximab	infliximab
RA treatment population	MTX resistant. No prior TNF therapy	MTX resistant. DAS28>=5.1	MTX resistant. DAS28>3.2. No prior TNF therapy	Active RA: No TNF in past 6 months	DMARD resistant. DAS28>3.2. No prior TNF therapy	MTX resistant	MTX resistant
Platform	Rosetta/Merck custom Affymetrix 2.0 microarray	Affymetrix Human Genome U133A Array	Illumina H-6 mRNA Sentrix Human-6 Expression BeadChip	Affymetrix Human Genome U133 Plus 2.0 Array	Affymetrix GeneChip Exon 1.0 ST	Agilent-014850 Whole Human Genome Microarray 4x44K G4112F	Agilent-014850 Whole Human Genome Microarray 4x44K G4112F
Efficacy	14-week EULAR criteria	14-week EULAR criteria	14-week EULAR criteria	14-week EULAR criteria	14-week EULAR Criteria	6-month CDAI	14-week serum CRP

863
864 GEO – gene expression omnibus; RA – rheumatoid arthritis; ACR – American College of Rheumatology; MTX –
865 methotrexate; EULAR – European League Against Rheumatism; DAS28 – disease activity score 28; TNF –
866 tumor necrosis factor; DMARD – disease modifying anti-rheumatic drugs; CRP – C-reactive protein; CDAI –
867 clinical disease activity index.

870 **Table 2 Discovery Algorithm Metrics**

	Analysis of data from MacIsaac et al.[16]
Training set: 9 placebo, 9 infliximab	
Errors/total	0/18
Accuracy	100%
Misclassification rate	0%
Validation set: 11 placebo, 10 infliximab	
Errors/total	0/21
Accuracy	100%
Misclassification rate	0%
Test set: 9 placebo, 11 infliximab	
Errors/total	0/20
Accuracy	100%
Misclassification	0%
Overall Accuracy	100%
Overall Sensitivity	100%
Overall Specificity	100%
Number of gene expression variables	4

873 **Table 3 Discovery Algorithm as Series of Operations**

Instruction	Input Registers	Explanation
r[03] = SINCPI(r[03])	r[03] = 19	Calculate the sine of 19, divide that by 19 and push the result (0.00788827419278696) into memory register 03
r[06] = SUB(r[13], r[02])	r[13] = KCTD4, r[02] = 7	Subtract 7 from the measurement of RNA KCTD4, then push the result into register 06
r[04] = ADD(r[15], r[01])	r[15] = Treatment_num, r[01] = 2	Add Treatment_num to 2 and push the result into register 04. Treatment_num 0 is placebo, Treatment_num 1 is infliximab.
r[05] = ADD(r[10], r[06])	r[10] = SPTY2D1	Add the value in register 06 to the measurement of RNA SPTY2D1 and push the result into register 05
r[01] = DIV(r[02], r[04])	r[02]= 7	Divide 7 by the value in register 04 and push the result into register 01
r[00] = SINCPI(r[09])	r[09] = UL84	Calculate the sine of the measurement of RNA UL84, divide that by the measurement of RNA UL84, and push the result into register 00
IF(r[00] < r[03])		If the value in register 00 is less than the value in register 03, then execute the following instruction, otherwise skip it
IF(r[11] < r[01])	r[11] = C1orf105	If the measurement of RNA C1orf105 is less than the value in register 01, then execute the following instruction, otherwise skip it
r[00] = ADD(r[04], r[05])		If both of the above IF statements are TRUE, then add the value in register 04 to the value in register 05 and push the result into register 00. If one or both of the above IF statements are false, skip this instruction.
r[05] = DIV(r[11], r[00])	r[11] = C1orf105	Divide the measurement of RNA C1orf105 by the value in register 00, and push the result into register 05
r[04] = CONSTDIV(7, 5)		Divide 7 by 5 and push the result into register 04
r[00] = ADD(r[04], r[05])		Add the value in register 04 to the value in register 05, and push the result into register 00
Final interpretation		If the contents of memory register 00 are negative, then patient is predicted to be a non-responder, otherwise a responder

Table 4 Gene Expression Variables

Expression Variable		Function
SPTY2D1	suppressor of Ty 5 homolog	tumor suppressor gene in thyroid cancer [24]
C1orf105	chromosome 1 open reading frame	vascular remodeling, coronary artery disease and atrial fibrillation [25,26]
KCTD4	potassium channel tetramerization domain containing 4	expressed in sepsis and esophageal cancer [27, 28]
UL84	gene for human CMV protein UL84	prior CMV infection associated with treatment response in RA [29,30]
PTPRC	Protein Tyrosine Phosphatase Receptor Type C or CD45	genetic variants associated with anti-TNF response in RA [31,32]
TPM3	Tropomyosin 3	tropomyosin isoform associated with neoplasia, myopathy and as an autoantigen in RA [33-35]
ARHGDIB	Rho GDP Dissociation Inhibitor Beta	negative regulator of Rho guanosine triphosphate (RhoGTP)ases, reduced in osteoarthritis synovial fluid and elevated in early RA synovial fluid [36,37]
SIAH1	Siah E3 Ubiquitin Protein Ligase 1	downregulated in both RA and tuberculosis, may influence amplitude of inflammatory gene response [38]

880 **Table 5 – Discovery and validation studies of blood-based gene expression data of**
881 **anti-TNF responsiveness in RA**

First author	MacIsaac [16]	Lequerre [18]	Julia [19]	Bienkowska [20]	Toonen [21]	Nakamura [22]	Tanino [23]
Number of patients	59	30	44	46 – leaving out intermediate responses or 75 including intermediate responses	42	140 (infliximab treated)	68
Classifier Method	OLS regression	UHC	SVM, DDA, RF, & k-NN	RF	K-means cluster analysis	Logistic regression	LOO
Cross-validation analyses	None	LOO	LOO	LOO, NN, LDA and SVM	None	None	None
Original reported results	None reported	Sens 90% Spec 70%	Sens 94% Spec 86%	Sens 88% Spec 84%	Sens 61% Spec 71%	Sens 79% Spec 47%	Sens 68% Spec 86%
Current analysis	Sens 100% Spec 100%	Sens 100% Spec 100%	Sens 100% Spec 86%	Sens 100% Spec 86%	Sens 100% Spec 96%	Sens 95% Spec 91%	Sens 96% Spec 84%

882
883 UHC – unsupervised hierarchical clustering; OLS – orthogonal least squares; LOO – leave one out; LDA - linear
884 discriminant analysis; SVM – support vector machine; RF – random forest; DLDA – Diagonal Linear Discriminant
885 Analysis; DQDA – Diagonal Quadratic Discriminant Analysis.

Supporting information

S1 File

- Sheet 1: Data excerpted from GSE58795 on 4 gene expression variables in discovery algorithm to enable validation
- Sheet 2: Summary gene expression for all eight variables by treatment group
- Sheets 3-8: x-y plots for DAS28 versus all eight variables by treatment group